245 related articles for article (PubMed ID: 26807718)
1. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.
Adema AY; van Ittersum FJ; Hoenderop JG; de Borst MH; Nanayakkara PW; Ter Wee PM; Heijboer AC; Vervloet MG;
PLoS One; 2016; 11(1):e0144121. PubMed ID: 26807718
[TBL] [Abstract][Full Text] [Related]
2. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
3. Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study.
Adema AY; de Roij van Zuijdewijn CLM; Hoenderop JG; de Borst MH; Ter Wee PM; Heijboer AC; Vervloet MG;
BMC Nephrol; 2018 Nov; 19(1):327. PubMed ID: 30442108
[TBL] [Abstract][Full Text] [Related]
4. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
5. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
6. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
8. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
[TBL] [Abstract][Full Text] [Related]
10. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study.
Nanayakkara PW; van Guldener C; ter Wee PM; Scheffer PG; van Ittersum FJ; Twisk JW; Teerlink T; van Dorp W; Stehouwer CD
Arch Intern Med; 2007 Jun; 167(12):1262-70. PubMed ID: 17592099
[TBL] [Abstract][Full Text] [Related]
11. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
Mukhin NA; Milovanova LY; Fomin VV; Kozlovskaya LV; Taranova MV; Androsova TV; Borisov AA
Klin Med (Mosk); 2017; 95(3):272-7. PubMed ID: 30303650
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
[TBL] [Abstract][Full Text] [Related]
13. In chronic kidney disease, serum α-Klotho is related to serum bicarbonate and proteinuria.
Hage V; Pelletier S; Dubourg L; Drai J; Cuerq C; Lemoine S; Hadj-Aissa A; Laville M; Fouque D
J Ren Nutr; 2014 Nov; 24(6):390-4. PubMed ID: 25193108
[TBL] [Abstract][Full Text] [Related]
14. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
[TBL] [Abstract][Full Text] [Related]
15. Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.
Shroff R; Aitkenhead H; Costa N; Trivelli A; Litwin M; Picca S; Anarat A; Sallay P; Ozaltin F; Zurowska A; Jankauskiene A; Montini G; Charbit M; Schaefer F; Wühl E;
J Am Soc Nephrol; 2016 Jan; 27(1):314-22. PubMed ID: 26069294
[TBL] [Abstract][Full Text] [Related]
16. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
[TBL] [Abstract][Full Text] [Related]
17. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
18. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
[TBL] [Abstract][Full Text] [Related]
19. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
